Barclays
TNDM icon

Barclays’s Tandem Diabetes Care TNDM Stock Holding History

Barclays’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.74M Buy
+90,600
New +$1.97M ﹤0.01% 2436
2024
Q2 		– Sell
-20,800
Closed -$737K – 5298
2024
Q1 		$737K Buy
+20,800
New +$557K ﹤0.01% 3342
2018
Q4 		– Sell
-88,000
Closed -$3.77M – 7326
2018
Q3 		$3.77M Buy
+88,000
New +$3.07M ﹤0.01% 2119

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays's TNDM Position: Q1 2026 in Review

Barclays reduced its Tandem Diabetes Care (TNDM) stake by 54% in Q1 2026, selling an estimated $10.8M and leaving 421,236 shares worth $8.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

Barclays first reported a position in TNDM in Q4 2013 and has held it in 47 quarters since. The position peaked at $20.2M in Q4 2025. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.

  • Barclays held 421,236 shares of Tandem Diabetes Care worth $8.08M as of Q1 2026.
  • Barclays sold 496,691 Tandem Diabetes Care shares in Q1 2026, an estimated $10.8M.
  • Tandem Diabetes Care made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1562 holding.
  • Barclays first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 47 quarters since.
  • Barclays's Tandem Diabetes Care position peaked at $20.2M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.